上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
VO-Ohpic trihydrate 纯度: ≥98.0%
VO-Ohpic trihydrate 是一种高效的 PTEN 抑制剂,IC50 为 46±10 nM。
VO-Ohpic trihydrate Chemical Structure
CAS No. : 476310-60-8
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥660 | In-stock | |
5 mg | ¥600 | In-stock | |
10 mg | ¥920 | In-stock | |
50 mg | ¥2744 | In-stock | |
100 mg | ¥4500 | In-stock | |
200 mg | ¥6800 | In-stock | |
500 mg | 询价 | ||
1 g | 询价 |
* Please select Quantity before adding items.
VO-Ohpic trihydrate 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- PI3K/Akt/mTOR Compound Library
- Stem Cell Signaling Compound Library
- Anti-Cancer Compound Library
- Autophagy Compound Library
- Anti-Aging Compound Library
- Oxygen Sensing Compound Library
- Glycolysis Compound Library
- Cytoskeleton Compound Library
- Anti-Pancreatic Cancer Compound Library
- Anti-Cancer Metabolism Compound Library
- Glucose Metabolism Compound Library
- Targeted Diversity Library
生物活性 |
VO-Ohpic trihydrate is a highly potent inhibitor of PTEN with an IC50 of 46±10 nM. |
IC50 & Target |
IC50: 46±10 nM (PTEN)[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
VO-OHpic with two OHpic ligands and an oxo ligand is a sterically demanding molecule, and one will therefore expect that binds substrate will affect the subsequent binding of the inhibitor due to steric hindrance. VO-OHpic significantly inhibits PTEN activity in low nanomolar concentrations (IC50, 46±10 nM), which is in agreement with the previously determined potency (IC50, 35±2 nM) in a PIP3-based assay. The inhibition constants Kic and Kiu are determined to be 27±6 and 45±11 nM, respectively[1]. VO-OHpic is an encouragingly specific and potent PTEN inhibitor. VO-OHpic is the most potent inhibitor (IC50=35 nM) of the PTEN lipid phosphatase activity[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
PTEN is inhibited in mice by intra-peritoneal injection of VO-OHpic (10 μg/kg) 30 min before ischemia and then exposed them to 30 min of ischemia and 120 min of reperfusion. At the end of the experiment, myocardial infarct size is measured by triphenyltetrazolium chloride (TTC). Myocardial infarct size is significantly decreased in VO-treated mice (25±6 vs. 56±5 %, n=7, P<0.01). There is no difference in the area at risk between these two groups (46±3 vs. 57±3 %, n=7, P>0.05)[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
415.20 |
||||||||||||||||
Formula |
C12H15N2O11V |
||||||||||||||||
CAS 号 |
476310-60-8 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 50 mg/mL (120.42 mM) H2O : < 0.1 mg/mL (insoluble) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
Kinase Assay [1] |
VO-OHpic is dissolved in DMSO (100 μM) and diluted further to the required concentration with 1% DMSO. For inhibition studies, PTEN is preincubated with VO-OHpic at RT for 10 min before substrate is added to initialise the reaction. Background absorbance (malachite green assay) and fluorescence (OMFP assay) are determined with VO-OHpic in assay buffer and corrected in the data analysis[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Animal Administration [3] |
Mice[3] 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务